Satyanarayana Chava, founder and CEO of Laurus Labs, saw his personal net worth cross $1.1 billion after shares of his company jumped this week.
Philippine Billionaire Ramon Ang’s San Miguel To Invest $1.9 Billion In Elevated Highway Along Pasig River
Laurus now has R&D units in Hyderabad, Visakhapatnam and the U.S. as well as eight FDA-approved factories in southern India for contract manufacturing and producing active pharma ingredients and intermediaries. Chava says he is not enamored by his billionaire status. “For me it’s just one part of life—it’s not the only thing,” he says attributing his down-to-earth approach to his modest upbringing.
In 1993, he took up his first corporate job as a research assistant with the erstwhile Ranbaxy Laboratories, a company that was eventually acquired by pharma billionaire Dilip Shanghvi’s Sun Pharmaceuticals. In 1995, he moved to Matrix Labs, a maker of pharma ingredients for HIV drugs, where he worked for the next decade in various divisions, eventually becoming COO. Matrix was taken over by global pharma major Mylan in 2006.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Indian Pharma Entrepreneur With A Passion For Research Joins Billionaire RanksSatyanarayana Chava, founder and CEO of Laurus Labs, saw his personal net worth cross $1.1 billion after shares of his company jumped this week.
Read more »
Curry Leaves Are a South Indian Herb With Major Star PowerThere's simply no substitute for fresh curry leaves, and they're absolutely worth seeking out.
Read more »
Indian Pharma Entrepreneur With A Passion For Research Joins Billionaire RanksSatyanarayana Chava, founder and CEO of Laurus Labs, saw his personal net worth cross $1.1 billion after shares of his company jumped this week.
Read more »
‘Enthusiastic Entrepreneurs’: Pre-IPO Statements On Profitability Prove To Be Larger Than Real LifeMore than one in four of the 50 largest venture-backed companies to go public since 2019 made assertions about their profitability that don’t appear to line up with their later IPO-related disclosures to the SEC, a new Forbes analysis has found.
Read more »